realworld dynamix™: biologic and jak switching in ra the clinician’s perspective on why the...
TRANSCRIPT
RealWorld Dynamix™: Biologic and JAK Switching in RA
Despite Rheumatologist Reports that BMS’ Orencia is Their Preferred Non-TNF Agent for Treating Rheumatoid Arthritis,
Pfizer’s Xeljanz Provides Steep Competition in Actual Switching Patterns. Patient Requests are a Key Driver Behind
Switching Brands in Rheumatoid Arthritis, according to a Recently Released Study by Spherix Global Insights.
RealWorld Dynamix™: Biologic JAK Switching in RA is a robust and deep patient chart analysis of 1,002 RA patients
who were switched from one biologic or Xeljanz to a different brand in the past three months. RealWorld Dynamix™
captures the clinician’s perspective on why the switch was made and the new brand chosen, as well as future intentions
should the response be suboptimal. In addition to patient demographics and treatment history, clinical assessments,
diagnostic tests and laboratory values are included to provide insight into the clinical course of the disease.
For more information contact: [email protected]
Self-Reported Current Line of Therapy for
Biologic Treated RA Patients
Number of Switches Since Initiation
Participating rheumatologists estimate that more than half of their biologic/JAK treated RA patients are on their
second or later line agent, with more than one quarter switching brands within the past year.
Similar to the prior year, the majority of recent switches are from first to second line agents, with TNF cycling
still highly prevalent.
First line Second line Third line
Percent of RA Patients Treated with Biologics
or Xeljanz Switched in Past Year
28%
Estimated annual percent of biologic and Xeljanz-treated
RA patients switched to a different brand (26% in 2016)
9% Two switches
(on third line biologic/JAK)
Percent of Switches From...
Perc
ent of patie
nts
83% First switch
(on second line biologic/JAK)
8% Three or more switches
(on fourth or later line
biologic/JAK)
Invest In Intelligence That Delivers
Level of Patient Involvements in Switch Decision
Overall, patients played a significant role or were the primary driver behind the decision to switch in nearly
two-thirds of the recent switches.
Orencia
Xeljanz
Rituxan
Kevzara
Actemra
Why Orencia is the Preferred Alternate MOA
After TNF Failure (Leading Reasons)
Safety/Tolerability
Efficacy
Experience
Specific MOA
Insurance/Cost
Dosing/Administration
In Cases Where the Patient Was the Primary Driver
of the Switch, Rheumatologists Report There Was…
No clinical
rationale
Some clinical
rationale
Strong clinical
rationale
What they did...
Percent of patients
Audited Second Line Share
What they said...
Self-reports indicate that Orencia is the leading alternative MOA, however, first switch analysis indicates
that Xeljanz captures more of the second line share in RA.
Rheumatologists’ Self-Reported Preference
for Alternative MOAs
OVERVIEW
There are currently nine biologics, one biosimilar, and one oral janus kinase (JAK) inhibitor approved for the treatment of rheumatoid arthritis (RA) in the United States. With the more established TNF-inhibiting biologics on the market for nearly two decades, RA treatment protocol and payer policy tend to dictate their use as first-line biologics. However, rheumatologists estimate that every year, roughly one-quarter of their RA patients treated with biologics or Xeljanz are switched from one biologic/JAK to another brand. Treatment protocols for second-line (and subsequent line) therapies are less stringent, resulting in a dynamic switching segment. This study provides independent analysis of the switching market, as the key driver and predictor of future brand share, delivering intelligence that is critical to informing commercial decisions.
SAMPLE & METHODOLOGY
RealWorld Dynamix™: Biologic/JAK Switching in RA (US) is based on a robust and deep patient chart analysis of ~1000 RA patients who were switched from one biologic or JAK-inhibitor to a different brand in the past three months. Each physician completes an in-depth medical history of their last five patients who met the study inclusion criteria. An excellent augmentation to claims data, RealWorld Dynamix™ also captures the clinician’s perspective on why the switch was made and the new brand chosen as well as future intentions should the response be suboptimal. In addition to patient demographics and treatment history, clinical assessments, diagnostic tests and laboratory values are included to provide insight into the clinical course of the disease.
KEY QUESTIONS ANSWERED
What is the patient profile of the typical RA “switch” patient, including demographics, co-morbid conditions, risk factors, concomitant treatments, lab values, and other information?
What drives biologic switching in RA and how does it differ by drug class and specific brands?
What do switch segment dynamics and physician intended use tell us about the future market share of approved brands?
How much influence does the patient have in the decision to switch biologic/JAK brands?
How do physicians determine success, over what time frame, and what are the next steps in the treatment algorithm?
What are the areas of opportunity and threat for the RA biologic brands and Xeljanz?
What is the awareness of the drugs in development and perceived positioning relative to others in the market?
Which patients are candidates for the drugs in the RA pipeline?
Products Profiled
Commercial Products
Roche/Genentech (Actemra), UCB (Cimzia), Amgen (Enbrel), AbbVie (Humira) BMS (Orencia), Janssen (Remicade, Simponi) Genentech/Biogen (Rituxan), Pfizer’s Xeljanz (tofacitinib), Celltrion/Pfizer (Inflectra), Sanofi/Regeneron (Kevzara)
Pipeline Agents
Incyte/Lilly (Olumiant), GSK/Janssen (sirukumab), AbbVie (upadacitinib)
Key Dates
August Publication
Deliverables
PowerPoint report with brand
specific sections
Frequency Tables and Summary
Statistics
On-site or web-based presentation
Copy of de-identified database
Related Reports 2017
RealTime Dynamix™: Rheumatoid
Arthritis US
RealWorld Dynamix™: Biologic/JAK
Switching in Rheumatoid Arthritis EU
RealTime Dynamix™: Rheumatoid
Arthritis EU
RealWorld Dynamix™: Biologic/Otezla
Switching in Psoriatic Arthritis US
RealTime Dynamix™: Psoriatic
Arthritis US
Pricing
$79,500
To order or to get more information, please contact
or call 484-879-4284 (US) or (41) 41 747 18 72 (EU)
Biologic/JAK Switching in Rheumatoid Arthritis (US)